Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy

M Lopez-Sublet; H Bihan; G Reach; S Dupont; A Didelot; J-J Mourad; A Krivitzky; R Dhote

doi:10.1016/j.diabet.2012.02.005

Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy

Diabetes Metab. 2012 Jun;38(3):273-5. doi: 10.1016/j.diabet.2012.02.005. Epub 2012 Mar 29.

Authors

M Lopez-Sublet¹, H Bihan, G Reach, S Dupont, A Didelot, J-J Mourad, A Krivitzky, R Dhote

Affiliation

¹ Post-Emergency Unit, Department of Internal Medicine, Hôpital Avicenne, 125, route de Stalingrad, 93009 Bobigny cedex, France. marilucy.lopez-sublet@avc.aphp.fr

PMID: 22463975
DOI: 10.1016/j.diabet.2012.02.005

Abstract

Glutamic acid decarboxylase antibodies (GAD-abs) are an immunological factor involved in type 1 diabetes and other diseases involving the central nervous system. This report is of a patient with type 1 diabetes and a rare case of non-paraneoplastic limbic encephalitis mediated by anti-GAD65 antibodies that improved with the use of immunosuppressive drugs.

Publication types

Case Reports

MeSH terms

Adult
Autoimmunity
Diabetes Mellitus, Type 1 / complications
Diabetes Mellitus, Type 1 / drug therapy
Diabetes Mellitus, Type 1 / immunology*
Female
Glutamate Decarboxylase / immunology*
Humans
Immunization, Passive / methods*
Immunoglobulins, Intravenous / administration & dosage*
Immunosuppressive Agents / therapeutic use
Limbic Encephalitis / drug therapy
Limbic Encephalitis / immunology*
Magnetic Resonance Imaging
Neuropsychological Tests
Treatment Outcome

Substances

Immunoglobulins, Intravenous
Immunosuppressive Agents
Glutamate Decarboxylase
glutamate decarboxylase 2